Abstract
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
Keywords: Estrogen receptor, hormone resistance, breast cancer
Current Cancer Drug Targets
Title: Overcoming Endocrine Resistance in Breast Cancer
Volume: 10 Issue: 5
Author(s): R.A. Madaio, G. Spalletta, L. Cravello, M. Ceci, L. Repetto and G. Naso
Affiliation:
Keywords: Estrogen receptor, hormone resistance, breast cancer
Abstract: Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
Export Options
About this article
Cite this article as:
Madaio R.A., Spalletta G., Cravello L., Ceci M., Repetto L. and Naso G., Overcoming Endocrine Resistance in Breast Cancer, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517226
DOI https://dx.doi.org/10.2174/156800910791517226 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Anticancer Studies of Leucovorin against Methotrexate Induced Genotoxicity in Swiss Albino Mice
Letters in Drug Design & Discovery Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets
Current Gene Therapy Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Contributions of the Interaction Between Dietary Protein and Gut Microbiota to Intestinal Health
Current Protein & Peptide Science Medicinal Potential of Heterocyclic Compounds from Diverse Natural Sources for the Management of Cancer
Mini-Reviews in Medicinal Chemistry REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Vinorelbine in Cancer Therapy
Current Drug Targets Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Meet the Editorial Board
Current Cancer Drug Targets Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design In Vitro, In Vivo and In Silico Analysis of the Anticancer and Estrogen-like Activity of Guava Leaf Extracts
Current Medicinal Chemistry Breast Cancer and Flavonoids - A Role in Prevention
Current Pharmaceutical Design Meet Our Associate Editor
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders
Current Drug Targets VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Antiestrogenic Therapies in Solid Cancers and Multiple Myeloma
Current Molecular Medicine